Fund Details
Nippon India Pharma Fund Direct Bonus
| Risk | Very High |
|---|---|
| Min SIP Amount | Not Supported |
| Expense Ratio | 0.82% |
| NAV | ₹287.65 (16 Apr 2021) |
|---|---|
| Fund Started | 01 Jan 2013 |
| Fund Size | ₹4,261 Cr |
Returns
Comparison
1. 1Y Returns are higher than the category average returns
2. 3Y Returns are higher than the category average returns
3. 5Y Returns are higher than the category average returns
Found nothing so far.
Top Holdings
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 11.2% |
| Aurobindo Pharma Ltd. | Healthcare | Equity | 9.9% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 9.8% |
| Cipla Ltd. | Healthcare | Equity | 9.8% |
| Lupin Ltd. | Healthcare | Equity | 9.6% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 8.9% |
| Fortis Healthcare Ltd. | Healthcare | Equity | 7.3% |
| Gland Pharma Ltd. | Healthcare | Equity | 6.4% |
| Cadila Healthcare Ltd. | Healthcare | Equity | 5.6% |
| Thyrocare Technologies Ltd. | Healthcare | Equity | 3.9% |
Fund Managers
Nippon India Pharma Fund Direct Bonus Details
Nippon India Pharma Fund Direct Bonus is a Equity Mutual Fund Scheme launched by Nippon India Mutual Fund. This scheme was made available to investors on 01 Jan 2013. Sailesh Raj Bhan is the Current Fund Manager of Nippon India Pharma Fund Direct Bonus fund.The fund currently has an Asset Under Management(AUM) of ₹4,261 Cr and the Latest NAV as of 16 Apr 2021 is ₹287.65.
The Nippon India Pharma Fund Direct Bonus is rated Very High risk. Minimum SIP Investment is set to 100. Exit load of 1% if redeemed within 1 month.
Investment Objective
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Tax Implications
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.
